- Home
- SEZL vs IMVT Comparison
SEZL vs IMVT Comparison
Compare SEZL & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- IMVT
- Stock Information
- Founded
- SEZL 2016
- IMVT 2018
- Country
- SEZL United States
- IMVT United States
- Employees
- SEZL N/A
- IMVT N/A
- Industry
- SEZL Diversified Financial Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEZL Finance
- IMVT Health Care
- Exchange
- SEZL Nasdaq
- IMVT Nasdaq
- Market Cap
- SEZL 2.2B
- IMVT 2.7B
- IPO Year
- SEZL N/A
- IMVT N/A
- Fundamental
- Price
- SEZL $55.81
- IMVT $23.98
- Analyst Decision
- SEZL Buy
- IMVT Buy
- Analyst Count
- SEZL 4
- IMVT 9
- Target Price
- SEZL $113.75
- IMVT $27.71
- AVG Volume (30 Days)
- SEZL 1.1M
- IMVT 1.7M
- Earning Date
- SEZL 11-05-2025
- IMVT 11-10-2025
- Dividend Yield
- SEZL N/A
- IMVT N/A
- EPS Growth
- SEZL 104.61
- IMVT N/A
- EPS
- SEZL 3.24
- IMVT N/A
- Revenue
- SEZL $418,632,890.00
- IMVT N/A
- Revenue This Year
- SEZL $65.77
- IMVT N/A
- Revenue Next Year
- SEZL $27.29
- IMVT N/A
- P/E Ratio
- SEZL $17.34
- IMVT N/A
- Revenue Growth
- SEZL 88.74
- IMVT N/A
- 52 Week Low
- SEZL $24.86
- IMVT $12.72
- 52 Week High
- SEZL $186.74
- IMVT $29.49
- Technical
- Relative Strength Index (RSI)
- SEZL 38.69
- IMVT 62.49
- Support Level
- SEZL $51.63
- IMVT $21.86
- Resistance Level
- SEZL $57.06
- IMVT $24.06
- Average True Range (ATR)
- SEZL 4.19
- IMVT 1.30
- MACD
- SEZL 0.75
- IMVT -0.24
- Stochastic Oscillator
- SEZL 31.98
- IMVT 76.18
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.